Drugdocs | Nuzyra

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Nuzyra

Chemical Name	omadacycline
Dosage Form	Injection (intravenous; 100 mg) Tablet (oral; 300 mg)
Drug Class	Tetracyclines
System	Respiratory, Skin
Company	Paratek Pharmaceuticals, Inc.
Approval Year	2018

Indication

To treat community-acquired bacterial pneumonia in adults.
To treat skin structure infections in adults.
To treat acute bacterial skin infections in adults.

Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Nuzyra (Omadacycline) Prescribing Information	2018	Paratek Pharmaceuticals, Inc., Boston, MA

Document Title	Year	Source
Novel tetracyclines versus alternative antibiotics for treating acute bacterial infection: A meta-analysis of randomized controlled trials.	2019	Antibiotics
The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.	2019	Medicine (Baltimore)